Olaf N.
- Country
- Germany
- Department
- n/a
Research Overview
- Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Adults With Active Psoriatic Arthritis: A Phase 3 Extension Study
- Long-Term Extension Study of RO7790121 (Afimkibart) for Safety and Efficacy in Adults with Moderate-to-Severe Rheumatoid Arthritis
- Efficacy and Safety Evaluation of Obinutuzumab in ISN/RPS 2003 Class III/IV Lupus Nephritis: A Phase III Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 172 of 305 partner sites.
Specializations
Autoimmune Disorders
This investigator specializes in studying therapeutic approaches for psoriatic arthritis, with particular emphasis on innovative treatment solutions for patients with varying response profiles.
- Treatment-naive patient populations
- Anti-TNFα inadequate responders
The research focuses on evaluating novel therapeutic interventions for managing inflammatory joint conditions.
Immunotherapy Research
The investigator explores targeted immunological treatments in rheumatology, particularly examining the therapeutic potential of novel biological agents.
- Biological DMARD therapies
- Subcutaneous treatment administration
- Comparative treatment efficacy
Their work encompasses the evaluation of different dosing regimens and treatment responses in autoimmune conditions.
Clinical Assessment
The investigator specializes in evaluating therapeutic outcomes using standardized response criteria in rheumatological conditions.
- ACR50 response measurements
- Placebo-controlled studies
- Active reference comparisons
Their expertise includes assessment of treatment efficacy in inflammatory arthritis conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.